85
Participants
Start Date
December 1, 2020
Primary Completion Date
April 30, 2023
Study Completion Date
July 1, 2028
Cisplatin+Albumin-bound paclitaxel (1 cycle) and PD-1 monoclonal antibody+Cisplatin+Albumin-bound paclitaxel (2 cycles)
PD-1 monoclonal antibody （SHR-1210)：200mg，IV infusion，Q3W Cisplatin：75-80 mg/m2, IV infusion, Q3W Albumin-bound paclitaxel: 260 mg/m2，30min，IV infusion, Q3W
Tongji Hospital, Wuhan
Women's Hospital School Of Medicine Zhejiang University
OTHER
Qilu Hospital of Shandong University
OTHER
Obstetrics & Gynecology Hospital of Fudan University
OTHER
First Affiliated Hospital of Chongqing Medical University
OTHER
Army Medical University, China
OTHER
Peking University People's Hospital
OTHER
Tianjin Medical University General Hospital
OTHER
The Second Affiliated Hospital of Harbin Medical University
OTHER
Chongqing University Cancer Hospital
OTHER
The First Affiliated Hospital of China University of Science and Technology (Anhui Provincial)
OTHER
Huazhong University of Science and Technology
OTHER